5 Orville Drive, Suite 200
84 articles about Sartorius
Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification
Sartorius and Repligen Corporation (NASDAQ:RGEN) today announced the launch of an integrated bioreactor system that incorporates Repligen XCell ® ATF upstream intensification technology into Sartorius’ Biostat STR® bioreactor, simplifying intensified seed train and N perfusion implementation for biopharmaceutical manufacturers.
Teknova and Sartorius BIA Separations Share Data Demonstrating Reliable and Scalable Approach for the Enhancement of AAV Full Capsid Enrichment with an Optimized AEX Platform
Alpha Teknova, Inc., and Sartorius BIA Separations, which is part of the international life science group Sartorius, shared new data that demonstrates the ability to improve the recovery of full AAV capsids during anion-exchange purification, which will help gene therapy companies streamline the downstream processing workflow.
Waters and Sartorius Expand Collaboration to Deliver Comprehensive Bioanalytics for Downstream Biomanufacturing
Waters Corporation and Sartorius announced a new collaboration to develop integrated analytical solutions for downstream biomanufacturing, expanding their joint agreement that began with upstream bioprocessing analytics.
Following extraordinary growth in 2020 and 2021, the life science group Sartorius again outperformed the market in fiscal 2022, achieving its targets for sales revenue and profitability.
In a challenging market environment, the life science group Sartorius successfully placed Schuldschein loans with a volume of 650 million euros.
The life science group Sartorius announced at the BioProcess International 2022 conference the launch of Sartobind® Rapid A, a ready-to-use, disposable membrane for monoclonal antibody capture.
The life science group Sartorius increased sales revenue and earnings with double-digit growth rates in the first half of 2022 and confirmed its full-year outlook.
Sartorius, a leading international partner of life science research and the biopharmaceutical industry, is further growing its global production capacity with the expansion of its manufacturing site in Tunisia.
On the occasion of its virtual Annual General Shareholders' Meeting today, life science company Sartorius takes a positive look back at the past year and provides shareholders with details on further growth prospects.
The life science group Sartorius has presented its 2021 Annual Report.
The life science group Sartorius announced that, through its subgroup Sartorius Stedim Biotech, it closed the acquisition of the Novasep chromatography division as of February 7, 2022, following approval by the U.S. Federal Trade Commission.
Due to the excellent development of its core business, additional demand generated by the coronavirus pandemic, and several acquisitions, the life science group Sartorius closed fiscal 2021 with exceptionally strong growth and a jump in profitability.
Sartorius strengthens its bioanalytics portfolio by acquiring a majority stake in ALS Automated Lab Solutions
The life science group Sartorius is expanding its bioanalytics portfolio by acquiring a majority stake in ALS Automated Lab Solutions GmbH.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Biopharma and life sciences organizations from across the globe provide updates on their pipelines and businesses.
BioNet and Sartorius’ Company BIA Separations Collaborate on Production Process Development of mRNA Vaccines
BioNet, a leading biotech company manufacturing genetically engineered vaccines, and BIA Separations, now part of Sartorius, a leading biochromatography development and manufacturing company, announced the successful development of an optimized mRNA manufacturing process.
Sartorius grows dynamically and profitably - Substantial double-digit increases in sales and earnings
The life science group Sartorius has continued to grow dynamically and profitably. For the nine-month reporting period of 2021, the company listed on the DAX since September recorded significant double–digit growth rates in sales and earnings.
Matica Bio Announces Joint Research Agreement with Sartorius for the Development of Advanced Viral Vector Manufacturing Technology
Matica Biotechnology, Inc today announced a joint research agreement (JRA) with Sartorius, a leading international partner of the biopharmaceutical industry.
Marked by recent announcements of new manufacturing sites, headquarters and job creations, the life science industry continues to thrive despite the COVID-19 pandemic.
The life science company Sartorius, through its subgroup Sartorius Stedim Biotech, acquired cell culture specialist Xell AG headquartered in Bielefeld, Germany.